Top Markets
#1 Cortex Cortex +32.75%
#2 Akedo Akedo +13.64%
#3 MarsCoin MarsCoin +13.33%
#4 龙虾 (Lobster) 龙虾 (Lobster) +12.39%
#5 Pons Pons +11.05%
#6 The Black Bull The Black Bull +10.44%
#7 Everything Everything +10.25%
#8 EXOD EXOD +9.04%
#9 Peapods Finance Peapods Finance +7.77%
#10 Official Trump Official Trump +7.45%
Coin of the day
Cortex Cortex
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Nanjing Leads Biolabs Co Ltd Nanjing Leads Biolabs Co Ltd

Nanjing Leads Biolabs Co Ltd

9887
Kedudukan dalam Saham #6818
Nanjing Leads Biolabs Co., Ltd. is a biotechnology firm currently in the... Nanjing Leads Biolabs Co., Ltd. is a biotechnology firm currently in the clinical development phase, dedicated to the global discovery, progression, and eventual market launch of innovative antibody-based medications. The company's therapeutic endeavors concentrate on various critical illnesses, including cancerous growths, autoimmune disorders, and other serious medical conditions. A prominent product in its development pipeline is LBL-024, a bispecific antibody engineered to target PD-L1 and 4-1BB, specifically for the treatment of extra-pulmonary neuroendocrine carcinoma. Other significant compounds under development include LBL-034, LBL-033, and LBL-007. Nanjing Leads Biolabs also leverages its proprietary LeadsBody platform, which focuses on CD3 T-cell engagers that have demonstrated promising anti-tumor effects and safety in preliminary studies, as well as the X-body platform, which specializes in 4-1BB/PD-L1 bispecific antibodies. Beyond these, the company is actively researching antibody treatments for oncological, autoimmune, and infectious diseases, and is also engaged in establishing tumor immunoassays. Established in 2012, its primary operations are based in Nanjing, China.
Harga Saham
$9.31
Modal Pasaran
$1.85B
Perubahan (1 hari)
1.04%
Perubahan (1 tahun)
22.21%
Negara
CN
Perdagangan Nanjing Leads Biolabs Co Ltd (9887)

Kategori

Healthcare
Nisbah P/E bagi Nanjing Leads Biolabs Co Ltd (9887)
Nisbah P/E pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Nanjing Leads Biolabs Co Ltd, nisbah P/E semasa (TTM) ialah 0. Pada akhir 2026, syarikat mempunyai nisbah P/E sebanyak 0.
Sejarah nisbah P/E bagi Nanjing Leads Biolabs Co Ltd dari 2026 hingga 2026
Nisbah P/E pada akhir setiap tahun
Tahun Nisbah P/E Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/E untuk syarikat serupa atau pesaing
Syarikat Nisbah P/E Perbezaan Nisbah P/E Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Cara membaca nisbah P/E

Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.

Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.

Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.